Accuray 2026 Q1 Earnings Revenue Declines 7.5%, Net Loss Widens 448%

Accuray (ARAY) reported Q1 2026 earnings on November 5, 2025, . The company reaffirmed its full-year 2026 revenue and adjusted EBITDA targets despite a significant widening of its net loss.

Revenue

Accuray’s total revenue declined 7.5% year-over-year to $93.94 million in Q1 2026, driven by a 23% drop in product revenue to $37.1 million. Service revenue, however, grew 7% to $56.8 million, partially offsetting the decline. The company attributed the product revenue shortfall to weaker performance in EIMEA and China, while service growth reflected ongoing demand for maintenance and support.

Earnings/Net Income

The company’s losses deepened significantly, with a net loss of $21.68 million in Q1 2026, . , a 350% wider loss. .

Post-Earnings Price Action Review

Following the earnings release, Accuray’s stock edged up 2.11% in the latest trading day and 0.69% for the week, . The mixed performance reflected investor uncertainty about near-term profitability but optimism about the company’s strategic initiatives, including cost-cutting measures and the launch of the Stellar system.

CEO Commentary

CEO acknowledged the “soft” results but highlighted progress in expanding CyberKnife and Radixact systems into new markets. He emphasized the Stellar system’s U.S. launch as a growth catalyst and outlined priorities: reducing costs, streamlining operations, and advancing partnerships for adaptive radiotherapy.

Guidance

Accuray reaffirmed its fiscal 2026 guidance, targeting total net revenue of $471–485 million and adjusted EBITDA of $31–35 million. As of September 30, 2025, cash and equivalents stood at $63.9 million, up from $58.0 million in June 2025.

Additional News

1. Restructuring Plan: Accuray initiated a restructuring effort to cut costs, .

2. Stellar Launch: The new Stellar system was unveiled at ASTRO, positioning the company for long-term growth in adaptive radiotherapy.

3. China Joint Venture Impact: Accounting rules deferred 49% of margins from shipments to the China JV, affecting reported gross margins.